Recent 8-K filings for XWEL
Highest-materiality recent filing
XWELL raises ~$31.3M via Series H convertible preferred and warrants; repurchases $9M of existing securities
- Gross proceeds ~$31.3M from sale of 31,333 Series H convertible preferred shares (convertible at $0.47/sh) and 66.7M warrants (exercise $0.345/sh, 3yr).
- Uses $9M of proceeds to repurchase $5.96M notes, redeem all Series G preferred, and redeem 8.8M warrants from institutional investors.
-
XWELL reports FY 2025 revenue of $29.2M, net loss $17.0M; $31.3M private placement in Feb 2026
Revenue $29.2M: XpresSpa $18.6M, XpresCheck $8.3M, Naples Wax Center $2.3M.
-
XWELL closes $31.3M private placement of Series H preferred and warrants; repurchases $9M notes
Aggregate gross proceeds of $31,333,000 from issuance of 31,333 Series H convertible preferred (conversion price $0.47) and warrants to purchase 66,665,957 common shares (exercise price $0.345).
-
Gross proceeds ~$31.3M from sale of 31,333 Series H convertible preferred shares (convertible at $0.47/sh) and 66.7M warrants (exercise $0.345/sh, 3yr).
-
XWELL shareholders approve reverse split, share issuance; reject board classification
Proposal 6 passed: authorizes reverse stock split at ratio 1:2 to 1:20, at Board's discretion within one year.
-
XWELL receives Nasdaq bid price deficiency notice; cure period through June 2026
Closing bid price below $1.00 for 30 consecutive business days ended Nov 28, 2025.
-
XWELL exchanges $1.55M Series G Preferred for $3.39M convertible notes; amends terms
Exchanged $1,553,806 Stated Value of Series G Preferred Stock (including accrued dividends) for $3,387,138.80 senior secured convertible notes.
-
XWELL reports Q3 2025 revenue of $7.3M, net loss narrows to $0.7M
Revenue $7.3M in Q3 2025; net loss attributable to XWELL $0.7M vs $4.8M in Q3 2024.
-
XWELL exchanges $1.55M Series G Preferred for $3.39M secured notes; warrants amended
Exchanged $1,553,806 aggregate Stated Value of Series G Preferred Stock for $3,387,138.80 senior secured convertible notes.
-
XWELL Q2 2025 revenue $7.7M, net loss $2.3M widens YoY
Revenue $7.7M, down from $9.3M YoY; sequential improvement from Q1 2025's $7.0M.
-
XWELL regains Nasdaq minimum bid price compliance; delisting risk removed
Received Nasdaq letter confirming compliance with Listing Rule 5550(a)(2) as bid price closed at or above $1.00 for 16 consecutive days.
-
XWELL Q1 revenue falls to $7.0M; net loss $4.7M; CDC contract extended 3 years
Revenue $7.0M, down 19% from $8.7M YoY; net loss attributable $4.7M vs $2.5M.
-
XWELL (XWEL) receives Nasdaq minimum bid price deficiency notice; cure period to Nov 10, 2025
Nasdaq notified XWELL on May 13, 2025 that its common stock's closing bid price was below $1.00 for 30 consecutive business days (Mar 31 - May 12, 2025).
-
XWELL dismisses Marcum, engages CBIZ CPAs; cites material weaknesses
Dismissed Marcum LLP and engaged CBIZ CPAs as auditor for FY2025, effective April 21, 2025.
-
XWELL reports FY 2024 revenue $33.9M (+13% YoY), net loss narrows to $16.9M
Revenue $33.9M (+13% YoY); gross margin rose to 26.3% from 12.2%.
-
Share issuance for Jan 2025 Series G Preferred and warrant financing approved (For: 1,329,306; Against: 328,079) to comply with Nasdaq listing rule.
-
XWELL plans medical spa acquisitions; $4M private placement to fund expansion by year-end 2025
Plan to acquire select medical spas by end of 2025, leveraging a $4M private placement.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.62 · Most common event other_material